The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Summit's therapy still remains years away from the market with a global late-stage trial being initiated in 2025, said J.P.

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Summit shared data from the HARMONi-2 study at the World Conference on Lung Cancer (WCLC) conference in San Diego.

Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...

This revenue flow is expected to continue growing with GlobalData predicting that the blockbuster will pull in $33.7bn in 2028, when key Keytruda patents are set to expire. Summit acquired ...

Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.

Its blockbuster Keytruda cancer drug is scheduled to lose patent protection by the end of this decade. The company is betting on an extensive candidate pipeline and new indications to drive long ...

As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda ...

Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

On the other hand, investors must assess some uncertainty regarding the Keytruda platform, which could lose its patent exclusivity by the end of this decade, forcing Merck to find a new growth driver.